<DOC>
	<DOCNO>NCT00270049</DOCNO>
	<brief_summary>The purpose study evaluate effect treatment epoetin alfa versus placebo percentage red blood cell anemic patient chronic lymphocytic ( white blood cell ) leukemia effect patient ' quality-of-life . Epoetin alfa genetically engineer protein stimulates red blood cell production .</brief_summary>
	<brief_title>Epoetin Alfa Treatment Anemia Resulting From Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>Cancer patient often experience anemia due disease , chemotherapy , . Quality life also affect , part fatigue associate anemia . Previous study epoetin alfa suggest achieve high hemoglobin level may improve quality life help patient live longer . This 12-week , double-blind , placebo-controlled , multicenter study determine effect treatment epoetin alfa percentage red blood cell anemic patient chronic white blood cell leukemia . At start study , patient either receive chemotherapy , single-agent chemotherapy , and/or prednisone ( steroid ) treatment . Patients randomly assign 2:1 receive either epoetin alfa placebo . Patients receive epoetin alfa receive subcutaneous ( skin ) epoetin alfa injection 3 time per week patient placebo receive equal volume match placebo , inject subcutaneously 3 time per week . Based patient ' rate increase red blood cell percentage , original dose 150 unit per kilogram 3 time per week may raise gradually 300 unit per kilogram 3 time per week , reach target red blood cell percentage 38 % 40 % . Patients achieve target red blood cell percentage eligible 12-week open-label extension study , focus safety finding . Effectiveness determine proportion patient reach target red blood cell percentage 38 % 40 % end study , number transfusion require , proportion patient achieve red blood cell percentage 38 % 40 % time study , change quality life parameter . Safety evaluation , include incidence adverse event , laboratory test , vital sign , perform throughout study . The hypothesis study epoetin alfa superior placebo increase percentage red blood cell target level , reduce number transfusion require , improve quality life . Epoetin alfa 150 unit per kilogram 3 time weekly subcutaneously 12 week . Individualized dose increase 50 mg/week depend red blood cell response , maximum 300 unit per kilogram 3 time per week obtain target level 38 % 40 % red blood cell .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Patients chronic lymphocytic ( white blood cell ) leukemia receive either cancer treatment , treat singleagent chemotherapy and/or prednisone one month combination chemotherapy regimen Performance score 0 ( fully active , disease restriction ) 3 ( capable limit selfcare , confine bed chair 50 % waking hour ) life expectancy least 6 month hematocrit &lt; 32 % , correct reticulocyte count &lt; 3 % , platelet &gt; 25,000 cells/millimeter cubed , creatinine &lt; 2.0 mg/mL , negative Coombs test ( test antibody red blood cell ) occult blood stool Patients clinically significant disease besides cancer uncontrolled high blood pressure history seizures receive androgen therapy within 2 month study receive transfusion within 1 week study entry receive radiation therapy within 1 month study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Anemia</keyword>
	<keyword>cancer</keyword>
	<keyword>leukemia</keyword>
	<keyword>chronic lymphocytic leukemia</keyword>
	<keyword>lymphocytic leukemia</keyword>
	<keyword>epoetin alfa</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>red blood cell</keyword>
	<keyword>transfusion</keyword>
	<keyword>quality life</keyword>
</DOC>